As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 382 million in 2013 at a compound annual growth rate of 7.6%. And insulin as the important diabetes medication has also seen increasing market size. In 2012 the global insulin market size reached US$20.8 billion, a year-on-year rise of 12.9%, basically monopolized by Novo Nordisk, Sanofi and Eli Lilly, which altogether accounted for 88.7% of market share.
To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/global-and-china-insulin-industry-report-2013-2017
Being the biggest diabetes power in the world, China currently has 98.4 million patients, accounting for about 25.8% of the world’s total. With the maturing of national health insurance system and improvement of economic level, the Chinese insulin drug market size has been on the rise, with the CAGR in 2007-2012 up to 25.4%, well above that of the global insulin market size, and it is expected to maintain a CAGR of at least 15% in the next few years.
Insulin has seen an increasing proportion of Chinese diabetes drug market, from 38.7% in 2007 to 55.6% in 2012. However, due to technical barriers, China’s insulin market is mainly occupied by Novo Nordisk, Sanofi and Eli Lilly, of which, Novo Nordisk accounted for 60.3% in 2012. While in recombinant human insulin market segments, the local Chinese enterprise –Tonghua Dongbao Pharmaceutical Co., Ltd. occupied part of the market with approximately 16% share.
Attracted by China’s tremendous diabetes drug market, multinational companies like Bayer, United Laboratories as well as the local Wanbang Biopharmaceuticals and Hisun Pharmaceutical are speeding up layout in China’s insulin market. Among them, Bayer Schering Pharma has obtained exclusive marketing and distribution rights of Poland’s Bioton insulin product “SciLin” in China as early as 2009; the recombinant Lispro Insulin of Wanbang Biopharmaceuticals has also received clinical approval issued by SFDA in September 2013.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/180845
Table of Content
1. Overview of Insulin
1.1 Definition
1.2 Classification
1.3 Industry Chain
2. Development of Global Insulin Market
2.1 Status Quo
2.2 Market Supply and Demand
2.3 Product R&D
2.4 Competition Pattern
2.5 Trends
3. Development of China Insulin Market
3.1 Status Quo
3.2 Market Supply and Demand
3.3 Import and Export
3.3.1 Insulin and Its Salts
3.3.1.1 Import and Export Value
3.3.1.2 Main Exporting Countries
3.3.1.3 Main Importing Countries
3.3.2 Non-dosed Insulin Containing Drugs
3.3.3 Dosed Insulin Containing Drugs
3.3.4 Insulin Imports of Typical Hospital
3.4 Competition Pattern
3.5 Market Price
3.6 Relevant Policies
3.7 Trends
To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/180845
4. Key Insulin Companies
4.1 Novo Nordisk
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D Expenditure
4.1.6 Insulin Business
4.1.7 Business in China
4.1.8 Development Forecast
4.2 Eli Lilly
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Insulin Business
4.2.7 Business in China
4.2.8 Prospects
4.3 Sanofi
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Insulin Business
4.3.7 Business in China
4.3.8 Prospects
4.4 Dongbao
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients
4.4.6 R&D and Investment
4.4.7 Insulin Business
4.4.8 Prospects
4.5 Wanbang Biopharmaceuticals
4.5.1 Profile
4.5.2 Operation
4.5.3 Insulin Business
4.6 Gan & Lee
4.6.1 Profile
4.6.2 Operation
4.7 Xinbai Pharmaceutical
4.7.1 Profile
4.7.2 Operation
5. Summary and Forecast
5.1 Comparison of Operations between International Giants and Local Chinese Enterprises
5.2 Industry Forecast
5.2.1 Number of Diabetic Patients in the World
5.2.2 Global Insulin Market Size
5.2.3 Number of Diabetic Patients in China
5.2.4 Chinese Insulin Market Size
About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Blog: http://industry-research-reports.blogspot.com/
To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/global-and-china-insulin-industry-report-2013-2017
Being the biggest diabetes power in the world, China currently has 98.4 million patients, accounting for about 25.8% of the world’s total. With the maturing of national health insurance system and improvement of economic level, the Chinese insulin drug market size has been on the rise, with the CAGR in 2007-2012 up to 25.4%, well above that of the global insulin market size, and it is expected to maintain a CAGR of at least 15% in the next few years.
Insulin has seen an increasing proportion of Chinese diabetes drug market, from 38.7% in 2007 to 55.6% in 2012. However, due to technical barriers, China’s insulin market is mainly occupied by Novo Nordisk, Sanofi and Eli Lilly, of which, Novo Nordisk accounted for 60.3% in 2012. While in recombinant human insulin market segments, the local Chinese enterprise –Tonghua Dongbao Pharmaceutical Co., Ltd. occupied part of the market with approximately 16% share.
Attracted by China’s tremendous diabetes drug market, multinational companies like Bayer, United Laboratories as well as the local Wanbang Biopharmaceuticals and Hisun Pharmaceutical are speeding up layout in China’s insulin market. Among them, Bayer Schering Pharma has obtained exclusive marketing and distribution rights of Poland’s Bioton insulin product “SciLin” in China as early as 2009; the recombinant Lispro Insulin of Wanbang Biopharmaceuticals has also received clinical approval issued by SFDA in September 2013.
Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/180845
Table of Content
1. Overview of Insulin
1.1 Definition
1.2 Classification
1.3 Industry Chain
2. Development of Global Insulin Market
2.1 Status Quo
2.2 Market Supply and Demand
2.3 Product R&D
2.4 Competition Pattern
2.5 Trends
3. Development of China Insulin Market
3.1 Status Quo
3.2 Market Supply and Demand
3.3 Import and Export
3.3.1 Insulin and Its Salts
3.3.1.1 Import and Export Value
3.3.1.2 Main Exporting Countries
3.3.1.3 Main Importing Countries
3.3.2 Non-dosed Insulin Containing Drugs
3.3.3 Dosed Insulin Containing Drugs
3.3.4 Insulin Imports of Typical Hospital
3.4 Competition Pattern
3.5 Market Price
3.6 Relevant Policies
3.7 Trends
To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/180845
4. Key Insulin Companies
4.1 Novo Nordisk
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D Expenditure
4.1.6 Insulin Business
4.1.7 Business in China
4.1.8 Development Forecast
4.2 Eli Lilly
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Insulin Business
4.2.7 Business in China
4.2.8 Prospects
4.3 Sanofi
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Insulin Business
4.3.7 Business in China
4.3.8 Prospects
4.4 Dongbao
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Clients
4.4.6 R&D and Investment
4.4.7 Insulin Business
4.4.8 Prospects
4.5 Wanbang Biopharmaceuticals
4.5.1 Profile
4.5.2 Operation
4.5.3 Insulin Business
4.6 Gan & Lee
4.6.1 Profile
4.6.2 Operation
4.7 Xinbai Pharmaceutical
4.7.1 Profile
4.7.2 Operation
5. Summary and Forecast
5.1 Comparison of Operations between International Giants and Local Chinese Enterprises
5.2 Industry Forecast
5.2.1 Number of Diabetic Patients in the World
5.2.2 Global Insulin Market Size
5.2.3 Number of Diabetic Patients in China
5.2.4 Chinese Insulin Market Size
About Us
MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.
Contact
M/s Sheela
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
Blog: http://industry-research-reports.blogspot.com/
No comments:
Post a Comment